3 Stocks That Have Tanked In 2017: What You Need To Know

The stock market is soaring.

The US bull market is chugging along for the 8th year in a row and while things are mostly good, not everyone has made it out a winner. Here’s what you need to know about the underdogs of 2017.

Fossil Group (NASDAQ: FOSL)

Retailers in general are having a tough time but Fossil Group is really feeling the pressure of an ever-increasingly competitive landscape. They have seen their market position in watch sales eroded by the appearance of the Apple Watch and they are also seeing double-digit declines in leathers, jewelry and a number of other product lines.

From a price of about $35 a share late last year, Fossil Group is now worth just about $6.50.

It’s hard to see where Fossil can turn it around. A big chunk of their sales, nearly half to be precise, comes from sales of licensed products. They have brands such as Armani Exchange, Diesel and Michael Kors but many of these brands are under fire.

Michael Kors is responsible for about a fifth of the group’s sales but has had to close down more than a hundred stores in 2017 as they try to dig themselves out of trouble.

Rite Aid (NYSE: RAD)

Rite Aid was never a high-flyer but they have seen their share price tumble from $8 all the way down to under $2 this year.

The pharmacy chain is in a struggling industry. Overall their space has seen a decline of 12% but clearly they have been hit harder than most. Their stock price took a nose dive when its merger with Walgreens got cancelled due to lack of signoff from the Federal Trade Commission.

Rite Aid has also been struggling to overcome below average pharmacy reimbursement rates. This means the company gets less money back and that eats into their bottom line. Their profits have been declining and as a result, the stock has followed.

Things could be looking up however, as a new deal has been agreed with Walgreens and the $4 billion cash injection could help pick themselves back up.

Allergan (NYSE: AGN)

Allergan looked like it was on the right track, reaching a high of nearly $260 a share back in the middle of the year but right they’re at $168 a share wondering what went wrong.

Investors are losing their patience with the pharmaceuticals company. The number of prescriptions written for their products are falling and while they have a lot of cash on hand, they don’t seem to be using it effectively.

The other problem is that they were dealt a loss in the courts. A Texas district court judge ruled against them in a case regarding their number one product, Restasis, a billion-dollar dry-eye medication. The ruling allowed a generic to enter the market before Allergan’s patent expired which means the moat they have worked hard to build is being eroded.

Investors pricing in the future know that replacing a rockstar drug is no easy feat and it remains to be seen if Allergan will continue the legal fight to try and protect their business or focus on research and development to try and groom a worthy successor. Either way it’s a distraction, and it means that the company could be adrift come the introduction of a generic competitor.

January 2, 2021 Update: We have just announced our BEST STOCK NEWSLETTER of 2020 AWARD!

CLICK HERE to find out which stock newsletter was up 78% in 2020 (and whose 2019 picks are now up 113%).

*** Our Award for BEST STOCK NEWSLETTER of 2020 ALERT ***

Updated January 2, 2021

At WallStreetSurvivor, we subscribe to dozens stock recommendation and advisory newsletters. There is ONE newsletter that is constantly outperforming all of the others--The Motley Fool Stock Advisor.

Five of their 2020 stock picks have doubled and the average return of all 24 of their stock picks for 2020 is up 78%!

We have been tracking ALL of the Motley Fool stock picks since January 2016. That's 5 years and 120 stock picks. As of Friday, January 1, 2021 the Motley Fool's January stock pick (TSLA) is up 720%, their March pick (ZM) is up 172%, their April pick of SHOP is up 226% and their June pick CRWD is up 120%; and another two have more than doubled. In addition, 10 of their 2019, 12 of their 2018, 11 of their 2017, 15 of their 2016. Most impressively, over the last 5 years that we have been tracking every recommendation, their average stock pick is up 209%--tht means over the last 5 years their stock picks, on average, have TRIPLED!

Now no one can guarantee that their next picks will be as strong, but our 5 years of experience has been super-profitable. The important thing about the Fool stock picks is you have to buy them the day they are recommended because they usually pop 5-10% in the first 72 hours after the release their recommendation. You sure don’t want to risk missing out on their next pick.

Normally the Fool service is priced at $199 per year but they are currently offering a NEW SUBSCRIBER DISCOUNT that allows you to get theiir next 24 stock picks for just $99/year. HERE is the LINK to visit their New Subscriber Discount page.

CLICK HERE to get access to all The Motley Fool’s Stock Picks and their next 12 months of picks for just $99 per Year! 



Robinhood was the first brokerage site to NOT charge commissions when they opened in 2013. They just past 10,000,000 accounts and to celebrate they are offering up to $1,000 in free stock when you open a new account.

Here’s the details: You must click on a special promo link to open your new Robinhood account. Then when you fund your account with at least $10, you will receive one stock valued between $5 and $500. Then, you will get a link to share with your friends. Every time one of your friends opens an account, you will receive another free stock valued between $5 and $500. Click here to learn more about this Special Robinhood offer.

Claim your free stock NOW (before it’s too late)

Comments are closed.